Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.

J Exp Clin Cancer Res · 2010 · PMC2890550 · PMID 20504361

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

a trend toward significancep = 0.085so close (0.05 < p ≤ 0.1)

On the other hand, BEVA does not seem to allow to achieve an higher rate of response, even if a trend toward significance (p = 0.085) is reported.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.